Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday August 14.
Carolyn Boroden of Fibonacciqueen.com thinks that Apple (AAPL), although it has rallied 40 points on the news Carl Icahn has a stake in the company, can go significantly higher. Apple has been making bullish crossover patterns over and over again and has rallied further over a longer period of time since its peak last September. Based on fibonacci ratios, Boroden thinks that the stock could, at minimum, go up to $561-582, with the longer term target of $792. Cramer thinks $792 is a bit high, but he does believe Apple can move higher. It trades at a low multiple of 12, should benefit from a turn in Europe and news of its latest iPhone is being greeted with perhaps unfairly low expectations. Cramer would use the bearish pin action off of Cisco's disappointment as an opportunity to buy Apple on a decline.
Cramer took some calls:
Fusion-io (FIO) is too speculative.
TiVo (TIVO) is involved in litigation and doesn't have enough growth. "I need growth in tech."
The Dow plunged 131 on worries the consumer is not spending. Macy's (M) disappointed for the first time in four years. Management blamed a cool spring for the decline, but the street is worried about broader implications for consumer spending. Homebuilders and housing-related plays were hit. In other sectors, Cisco (CSCO) reported in-line numbers, but the stock fell 10%. Cramer would not sell Cisco at this level. Cree (CREE) disappointed, because expectations were too high. There are many things going right in this market, but Cramer would trade with caution.
Cramer took some calls:
Agco (AGCO) is a good agriculture stock.
Cummins (NYSE:CMI) is a stock worth buying on a pullback, because of its natural gas engine.
Sears Holdings (SHLD) is not that good a stock, but Cramer would not short it.
CEO Interview: Daniel Junius, ImmunoGen (NASDAQ:IMGN)
ImmunoGen (IMGN) partnered up with drug company Roche to develop a breast cancer drug designed to kill only cancer cells and to leave the healthy cells alone. The drug is in its early stages of approval, but there is some criticism that the royalty agreement is not beneficial to IMGN, which receives only 3-5% of sales. CEO Daniel Junius thinks the drug could potentially be a multi-billion dollar opportunity, and thinks IMGN will benefit significantly. UBS downgraded IMGN over concerns about toxicity in trials for its ovarian cancer and lymphoma drugs. Junius says he is "surprised" at these comments, because when drugs are being tested, there is a trial and error process with dosage until the right level is found. Cramer pointed out that the stock has risen 36% since December and it has many good drugs in the pipeline.
Jim Cramer's Action Alerts PLUS: Trade right alongside a Wall Street pro! Start your 14-day FREE trial today.
Get Cramer's Picks by email - it's free and takes only a few seconds to sign up.